Anti-Misfolding and Anti-Fibrillization Therapies for Protein Misfolding Disorders

Protein Misfolding Diseases: Current and Emerging Principles and Therapies

Volumn , Issue , 2010, Pages 933-944

  Martin, Zane ^a   Soto, Claudio ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Amyloid binding proteins as natural inhibitors of protein misfolding and aggregation; Anti misfolding and anti fibrillization therapies for protein misfolding disorders; Peptide inhibitors of protein misfolding rational development of specific inhibitors, based on use of short peptides targeting

Indexed keywords

EID: 84876843990     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470572702.ch43     Document Type: Chapter

References (67)

1. Makin, O.S., Serpell, L.C. (2002). Examining the structure of the mature amyloid fibril. Biochem Soc Trans, 30, 521-525.
2. Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci, 4, 49-60.
3. Osborne, B.M., Butler, J.J., Mackay, B. (1979). Proteinaceous lymphadenopathy with hypergammaglobulinemia. Am J Surg Pathol, 3, 137-145.
4. Wolman, M., Bubis, J.J. (1965). The cause of the green polarization color of amyloid stained with Congo Red. Histochemie, 4, 351-356.
5. Hardy, J. (2001). Genetic dissection of primary neurodegenerative diseases. Biochem Soc Symp, 51-57.
6. Selkoe, D.J. (1994). Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol, 53, 438-447.
7. Katzman, R. (1988). Alzheimer's disease as an age-dependent disorder. Ciba Found Symp, 134, 69-85.
8. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C.V., Checler, F., Horowitz, P., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem, 274, 6483-6492.
9. Walsh, D.M., Selkoe, D.J. (2004). Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett, 11, 213-228.
10. Selkoe, D.J. (2002). Alzheimer's disease is a synaptic failure. Science, 298, 789-791.
11. Chromy, B.A., Nowak, R.J., Lambert, M.P., Viola, K.L., Chang, L., Velasco, P.T., Jones, B.W., Fernandez, S.J., Lacor, P.N., Horowitz, P., et al. (2003). Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry, 42, 12749-12760.
12. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J., Teplow, D.B. (1999). Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem, 274, 25945-25952.
13. Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T., Jr. (1999). Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry, 38, 8972-8980.
14. Lin, Y.M., Raffen, R., Zhou, Y., Cassidy, C.S., Flavin, M.T., Stevens, F.J. (2001). Amyloid fibril formation in microwell plates for screening of inhibitors. Amyloid, 8, 182-193.
15. Modler, A.J., Gast, K., Lutsch, G., Damaschun, G. (2003). Assembly of amyloid protofibrils via critical oligomers: a novel pathway of amyloid formation. J Mol Biol, 325, 135-148.
16. Teplow, D.B. (1998). Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid, 5, 121-142.
17. Levine, H., III. (1995). Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. Neurobiol Aging, 16, 755-764.
18. Cardone, M. (2007). Prospects for gene therapy in inherited neurodegenerative diseases. Curr Opin Neurol, 20, 151-158.
19. Boudreau, R.L., Davidson, B.L. (2006). RNAi therapy for neurodegenerative diseases. Curr Top Dev Biol, 75, 73-92.
20. Koutsilieri, E., Rethwilm, A., Scheller, C. (2007). The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders. J Neural Transm Suppl, 43-49.
21. Kan, I., Melamed, E., Offen, D. (2007). Autotransplantation of bone marrowderived stem cells as a therapy for neurodegenerative diseases. Handb Exp Pharmacol, 219-242.
22. Sonntag, K.C., Sanchez-Pernaute, R. (2006). Tailoring human embryonic stem cells for neurodegenerative disease therapy. Curr Opin Investi Drugs, 7, 614-618.
23. Golabek, A., Marques, M.A., Lalowski, M., Wisniewski, T. (1995). Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett, 191, 79-82.
24. Soto, C., Ghiso, J., Frangione, B. (1997). Alzheimer's amyloid-b aggregation is modulated by the interaction of multiple factors. Alzheimer's Res, 3, 215-222.
25. Evans, K.C., Berger, E.P., Cho, C.G., Weisgraber, K.H., Lansbury, P.T., Jr. (1995). Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A, 92, 763-767.
26. Matsubara, E., Soto, C., Governale, S., Frangione, B., Ghiso, J. (1996). Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J, 316 (Pt 2), 671-679.
27. Schwarzman, A.L., Gregori, L., Vitek, M.P., Lyubski, S., Strittmatter, W.J., Enghilde, J.J., Bhasin, R., Silverman, J., Weisgraber, K.H., Coyle, P.K. (1994). Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A, 91, 8368-8372.
28. Janciauskiene, S., Garcia, D.F., Carlemalm, E., Dahlback, B., Eriksson, S. (1995). Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem, 270, 26041-26044.
29. Janciauskiene, S., Rubin, H., Lukacs, C.M., Wright, H.T. (1998). Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J Biol Chem, 273, 28360-28364.
30. Castillo, G.M., Lukito, W., Peskind, E., Raskind, M., Kirschner, D.A., Yee, A.G., Snow, A.D. (2000). Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain. J Neurosci Res, 62, 451-462.
31. Bronfman, F.C., Garrido, J., Alvarez, A., Morgan, C., Inestrosa, N.C. (1996). Laminin inhibits amyloid-beta-peptide fibrillation. Neurosci Lett, 218, 201-203.
32. Castano, E.M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R.A., Soto, C., Frangione, B. (1995). Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J, 306 (Pt 2), 599-604.
33. Ma, J., Yee, A., Brewer, H.B., Jr., Das, S., Potter, H. (1994). Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature, 372, 92-94.
34. Hamazaki, H. (1995). Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem Biophys Res Commun, 211, 349-353.
35. Geerts, H. (2004). NC-531 (Neurochem). Curr Opin Invest Drugs, 5, 95-100.
36. Hetz, C.A., Soto, C. (2006). Stressing out the ER: a role of the unfolded protein response in prion-related disorders. Curr Mol Med, 6, 37-43.
37. Chaudhuri, T.K., Paul, S. (2006). Protein misfolding diseases and chaperone-based therapeutic approaches. FEBS J, 273, 1331-1349.
38. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999). Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
39. Schenk, D., Hagen, M., Seubert, P. (2004). Current progress in beta-amyloid immunotherapy. Curr Opin Immunol, 16, 599-606.
40. Sigurdsson, E.M. (2006). Immunotherapy for conformational diseases. Curr Pharm Des, 12, 2569-2585.
41. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 6, 916-919.
42. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 98, 8850-8855.
43. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P.M., Jucker, M. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 298, 1379.
44. Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61, 46-54.
45. Spinney, L. (2004). Update on Elan vaccine for Alzheimer's disease. Lancet Neurol, 3, 5.
46. Hock, C., Konietzko, U., Streffer, J.R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003). Antibodies against betaamyloid slow cognitive decline in Alzheimer's disease. Neuron, 38, 547-554.
47. Estrada, L.D., Yowtak, J., Soto, C. (2006). Protein misfolding disorders and rational design of antimisfolding agents. Methods Mol Biol, 340, 277-293.
48. De Lorenzi, E., Giorgetti, S., Grossi, S., Merlini, G., Caccialanza, G., Bellotti, V. (2004). Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease." Curr Med Chem, 11, 1065-1084.
49. Cohen, F.E., Kelly, J.W. (2003). Therapeutic approaches to protein misfolding diseases. Nature, 426, 905-909.
50. Soto, C. (2001). Protein misfolding and disease; protein refolding and therapy. FEBS Lett, 498, 204-207.
51. Mason, J.M., Kokkoni, N., Stott, K., Doig, A.J. (2003). Design strategies for antiamyloid agents. Curr Opin Struct Biol, 13, 526-532.
52. Estrada, L.D., Soto, C. (2006). Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des, 12, 2557-2567.
53. Tjernberg, L.O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A.R., Thyberg, J., Terenius, L., Nordstedt, C. (1996). Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem, 271, 8545-8548.
54. Ghanta, J., Shen, C.L., Kiessling, L.L., Murphy, R.M. (1996). A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem, 271, 29525-29528.
55. Pallitto, M.M., Ghanta, J., Heinzelman, P., Kiessling, L.L., Murphy, R.M. (1999). Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry, 38, 3570-3578.
56. Findeis, M.A., Musso, G.M., Arico-Muendel, C.C., Benjamin, H.W., Hundal, A.M., Lee, J.J., Chin, J., Kelley, M., Wakefield, J., Hayward, N.J., Molineaux, S.M. (1999). Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry, 38, 6791-6800.
57. Findeis, M.A., Lee, J.J., Kelley, M., Wakefield, J.D., Zhang, M.H., Chin, J., Kubasek, W., Molineaux, S.M. (2001). Characterization of cholyl-leu-val-phe-pheala-OH as an inhibitor of amyloid beta-peptide polymerization. Amyloid, 8, 231-241.
58. Hughes, E., Burke, R.M., Doig, A.J. (2000). Inhibition of toxicity in the betaamyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem, 275, 25109-25115.
59. Gordon, D.J., Sciarretta, K.L., Meredith, S.C. (2001). Inhibition of betaamyloid( 40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry, 40, 8237-8245.
60. Soto, C., Kindy, M.S., Baumann, M., Frangione, B. (1996). Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun, 226, 672-680.
61. Soto, C. (1999). Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today, 5, 343-350.
62. Wood, S.J., Wetzel, R., Martin, J.D., Hurle, M.R. (1995). Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry, 34, 724-730.
63. Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M., Frangione, B. (1998). Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med, 4, 822-826.
64. Sigurdsson, E.M., Permanne, B., Soto, C., Wisniewski, T., Frangione, B. (2000). In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol, 59, 11-17.
65. Permanne, B., Adessi, C., Fraga, S., Frossard, M.J., Saborio, G.P., Soto, C. (2002). Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J Neural Transm Suppl, 293-301.
66. Chacon, M.A., Barria, M.I., Soto, C., Inestrosa, N.C. (2004). b-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry, 9, 953-961.
67. Adessi, C., Soto, C. (2002). Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem, 9, 963-978.